Homepage

InflaRx N.V.

IFRX NASDAQ Categories PDF
Healthcare · Biotechnology · Germany · Updated May 11, 1:54pm
$2.60
Price
$187.6M
Market Cap
74
Employees
2.44
Beta
Niels C. Riedemann
CEO
Business Description

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Business History
Price Overview
Last updated: May 11, 2026 1:54pm (just now)
$2.60
+0.02 (+0.58%)
Day Range
$2.51 – $2.72
52-Week Range
$0.71 – $2.95
50-Day MA
$1.27
200-Day MA
$1.17
Volume
2,402,543.31
Analyst Price Targets
Low $2.00
Consensus $2.00
High $2.00
(3 analysts)
Share Structure
Outstanding 72,292,859.00
Float 60,014,640.00
Free Float 83.0%
High free float — 83.0% of shares trade freely, ~17% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
API Direct from provider CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALC
Stock Price / EPS (Diluted)
-3.93
Stock Price: $2.60
EPS (Diluted): -0.66
P/B Ratio (Price vs net asset value)
API
Stock Price / Book Value Per Share
1.39
Stock Price: $2.60
Total Equity: $41.54M
Shares: 67,288,321
EV/EBITDA (Total value vs operating profit)
API
Enterprise Value / EBITDA
-3.07
Market Cap: $187.60M
Total Debt: $256,833
Cash: $16.02M
EBITDA: -$48.50M
Enterprise Value (Takeover price (cap + debt - cash))
API
Market Cap + Total Debt - Cash
$42.7M
Market Cap: $187.60M
Total Debt: $256,833
Cash: $16.02M
Gross Margin (Revenue left after direct costs)
API
Gross Profit / Revenue
-26,108.5%
Gross Profit: -$7.36M
Revenue: $28,173
Operating Margin (Revenue left after all operations)
API
Operating Income / Revenue
-173,594.0%
Operating Income: -$48.91M
Revenue: $28,173
Net Margin (Revenue left as actual profit)
API
Net Income / Revenue
-155,584.2%
Net Income: -$43.83M
Revenue: $28,173
ROE (Profit from shareholder equity)
API
Net Income / Total Equity
-91.1%
Net Income: -$43.83M
Total Equity: $41.54M
ROIC (Profit from all invested capital)
API
NOPAT / Invested Capital
-113.4%
Operating Income: -$48.91M
Tax Rate: 0.0%
Equity: $41.54M
Total Debt: $256,833
Cash: $16.02M
Current Ratio (Can it pay short-term bills)
API
Current Assets / Current Liabilities
4.13
Current Assets: $53.61M
Current Liabilities: $12.98M
Debt/Equity (Leverage — debt vs equity)
CALC
Total Debt / Total Equity
0.01
Short-Term Debt: $256,833
Long-Term Debt: $0.00
Total Debt: $256,833
Total Equity: $41.54M
Rev/Share (Top-line per share)
CALC
Revenue / Shares Outstanding
$0.00
Revenue: $28,173
Shares: 67,288,321
Book Value/Share (Net assets per share)
CALC
(Total Assets - Total Liabilities) / Shares
$0.62
Total Equity: $41.54M
Shares: 67,288,321
FCF/Share (Real cash generated per share)
CALC
(Operating Cash Flow + CapEx) / Shares
$-0.51
Operating CF: -$33.92M
CapEx: -$111,127
Shares: 67,288,321
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
API
Last Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.60
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$43.83M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares IFRX against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Deep Analysis

Pre-flight intelligence scans the company first, then routes to the right analytical methods.

0 Company Classification — What type of company is this?
1 Industry Landscape — Where is the industry headed?
2 Company Momentum — Where is this company trending?
3 Forward Projection — 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a DCF Valuation — Present value of future cash flows
4b Earnings Power Value — Floor value — worth with zero growth
4c Anchored PE — Industry PE adjusted for growth differential
4d Reverse DCF — What growth is the market pricing in?
4e Revenue-Based DCF — For growth/narrative companies (skip if mature earner)
4f Anchored P/S — Price-to-Sales peer comparison (skip if mature earner)
4g Scenario Analysis — Bull / Base / Bear (skip if mature earner)
4h Dividend Discount Model — For dividend/income stocks only
4i Book Value Analysis — For deep value / turnaround stocks only
4j Insider Activity — Are insiders buying or selling?
4f Cash Flow Quality — How trustworthy is the FCF?
4g Debt Maturity Risk — Can it handle its debt?
4h Macro Environment — Rates, market valuation, volatility
4i Sector Intelligence — How does this company compare within its sector?
4j Revenue Confidence — How reliable is the growth projection?
4k Sensitivity Analysis — How fragile is the fair value estimate?
4l Sector Demand Cycle — Is the sector in a boom, steady state, or contraction?
5 AI Investigation — Adaptive research engine (Claude)
5b Thesis Evaluation — What does the market believe? (narrative/platform stocks only)
6 Valuation Synthesis — Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Metric 2021 2022 2023 2024 2025
Revenue $0 $0 $63,089 $165,789 $28,173
Cost of Revenue $791,258 $627,008 $532,262 $3.3M $7.4M
Gross Profit $-791,258 $-627,008 $-469,173 -$3.2M -$7.4M
Operating Expenses $55.6M $54.4M $44.4M $49.9M $41.6M
Operating Income -$56.4M -$55.1M -$44.9M -$53.0M -$48.9M
Net Income -$53.9M -$31.0M -$42.7M -$46.1M -$43.8M
EBITDA -$53.1M -$30.3M -$42.1M -$45.6M -$48.5M
EPS $-1.10 $-0.61 $-0.78 $-0.78 $-0.66
EPS (Diluted) — — — — —
Balance Sheet (Annual)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $26.2M $16.3M $12.8M $18.4M $16.0M
Total Current Assets $95.7M $97.4M $109.5M $71.7M $53.6M
Total Assets $125.1M $102.4M $120.2M $76.0M $55.2M
Current Liabilities $18.8M $13.0M $16.8M $14.2M $13.0M
Long-Term Debt $0 $0 $0 $0 $0
Total Liabilities $19.9M $14.1M $17.6M $14.6M $13.7M
Total Equity $105.3M $88.3M $102.6M $61.4M $41.5M
Retained Earnings -$214.0M -$243.5M -$286.1M -$332.2M -$377.7M
Cash Flow (Annual)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow -$39.9M -$33.7M -$37.8M -$48.6M -$33.9M
Capital Expenditure $-37,778 $-162,391 $-81,100 $-46,871 $-111,127
Free Cash Flow -$40.0M -$33.9M -$37.9M -$48.6M -$34.0M
Acquisitions (net) $37,778 -$19.5M $0 $0 $0
Debt Repayment — — — — —
Dividends Paid — — — — —
Stock Buybacks $0 $0 $0 $0 $0
Net Change in Cash $281,314 -$10.0M -$3.5M $5.6M $-179,657
Analyst Estimates (Annual)
Metric 2027 2028 2029 2030
Revenue $16,585
$14,373 – $19,902
 $11,881
$10,296 – $14,257
 $19,349
$16,769 – $23,218
 $47.8M
$41.4M – $57.3M
EBITDA $-3,316
$-3,980 – $-2,874
 $-2,376
$-2,851 – $-2,059
 $-3,869
$-4,643 – $-3,353
 -$9.6M
-$11.5M – -$8.3M
Net Income -$39.5M
-$47.0M – -$34.9M
 -$29.6M
-$37.3M – -$24.5M
 -$31.4M
-$39.5M – -$25.9M
 -$26.2M
-$33.0M – -$21.7M
EPS — — — —
Growth Trends (YoY %)
Metric 2022 2023 2024 2025
Revenue Growth — — +162.8% -83.0%
Gross Profit Growth +20.8% +25.2% -571.7% -133.4%
Operating Income Growth +2.3% +18.4% -18.0% +7.7%
Net Income Growth +42.5% -37.7% -8.0% +4.8%
EBITDA Growth +42.9% -38.8% -8.3% -6.5%
Insider Trading (Recent)
Date Insider Type Shares Price Value
2026-03-18 Kubler Mark 0.00 $0.00 $0
2026-03-18 Kubler Mark 7,308.00 $0.01 $96
2026-03-18 Kubler Mark 30,000.00 $1.86 $55,800
2026-03-18 Kubler Mark 30,000.00 $2.37 $71,100
2026-03-18 Kubler Mark 30,000.00 $1.79 $53,700
2026-03-18 Kubler Mark 30,000.00 $2.41 $72,300
2026-03-18 Kubler Mark 30,000.00 $1.17 $35,100
2026-03-18 Gibney Anthony S 0.00 $0.00 $0
2026-03-18 Gibney Anthony S 30,000.00 $1.86 $55,800
2026-03-18 Gibney Anthony S 30,000.00 $2.37 $71,100
2026-03-18 Gibney Anthony S 30,000.00 $1.79 $53,700
2026-03-18 Gibney Anthony S 30,000.00 $2.41 $72,300
2026-03-18 Gibney Anthony S 30,000.00 $1.17 $35,100
2026-03-18 OCarroll Derval 20,000.00 $2.44 $48,800
2026-03-18 OCarroll Derval 25,000.00 $2.37 $59,250
2026-03-18 OCarroll Derval 45,000.00 $1.79 $80,550
2026-03-18 OCarroll Derval 70,000.00 $2.41 $168,700
2026-03-18 OCarroll Derval 70,000.00 $1.17 $81,900
2026-03-18 OCarroll Derval 21,000.00 $1.17 $24,570
2026-03-18 Fulpius Nicolas 0.00 $0.00 $0
Community AI Feedback
Sign in to Contribute
No community reviews yet for IFRX. Be the first — export the analysis to your AI and contribute back.
My Notes personal — only you see this
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.193 · 1946f027 · 2026-05-08 18:57:27